Pancreatic Cancer Research

ResearcherUniversity Medical Center Hamburg-EppendorfActive in the last 2 years

Florian Gebauer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5312-4814; OpenAlex author ID A5033025650. Sources: OpenAlex.

Their work

Papers
22 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
45
Papers, trials and grants by year

2011: 4 papers · 2012: 1 paper · 2013: 1 paper · 2014: 4 papers · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 22

  1. Oncogenic KRAS Regulates Secretion of Extracellular Vesicles and Surface Membrane Charge via Regulation of Phosphatidylserine in Pancreatic Cancer. Co-author DOI 10.1021/acsnano.6c08263↗
  2. Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures. Co-author DOI 10.1016/j.ebiom.2024.105219↗
  3. Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression. Co-author DOI 10.1186/s13046-021-01946-2↗
  4. [Molecular predictors for the course of disease and individualized therapy in pancreatic cancer]. First author DOI 10.1007/s00104-020-01172-0↗
  5. Proposal for a definition of "Oligometastatic disease in pancreatic cancer". Co-author DOI 10.1186/s12885-019-6448-9↗
  6. [Oligometastasis in pancreatic cancer : Current state of knowledge and spectrum of local therapy]. Co-author DOI 10.1007/s00104-018-0626-1↗
  7. Improved Risk Stratification by Circulating Tumor Cell Counts in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-18-0120↗
  8. Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer. Co-author DOI 10.1080/15384047.2017.1281499↗
  9. Is hyaluronan deposition in the stroma of pancreatic ductal adenocarcinoma of prognostic significance? Co-author DOI 10.1371/journal.pone.0178703↗
  10. Pancreatic cancer and liver metastases: state of the art. First author DOI 10.1007/s13304-016-0407-7↗
  11. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicent… First author DOI 10.1016/j.surg.2016.02.019↗
  12. Resection margin clearance in pancreatic cancer after implementation of the Leeds Pathology Protocol (LEEPP): clinically relevant or just academic? Co-author DOI 10.1007/s00268-014-2808-4↗
  13. ABO blood group IgM isoagglutinins interact with tumor-associated O-glycan structures in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-14-0716↗
  14. Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinom… First author DOI 10.1186/1471-2407-14-411↗
  15. Carcinoembryonic antigen-related cell adhesion molecules (CEACAM) 1, 5 and 6 as biomarkers in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0113023↗
  16. Serum EpCAM expression in pancreatic cancer. Co-author PMID 25202052↗
  17. Selectin binding is essential for peritoneal carcinomatosis in a xenograft model of human pancreatic adenocarcinoma in pfp--/rag2-- mice. Co-author DOI 10.1136/gutjnl-2011-300629↗
  18. ALCAM (CD166) expression and serum levels in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0039018↗
  19. Heme oxygenase-1 germ line GTn promoter polymorphism is an independent prognosticator of tumor recurrence and survival in pancreatic cancer. Co-author DOI 10.1002/jso.21926↗
  20. Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.21957↗
  21. Multivisceral resections in pancreatic cancer: identification of risk factors. Co-author DOI 10.1007/s00268-011-1263-8↗
  22. Bypass surgery versus intentionally incomplete resection in palliation of pancreatic cancer: is resection the lesser evil? Co-author DOI 10.1007/s11605-011-1469-y↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Tachezy · 14 shared papers, 2011–2021 · strength 0.71
  2. Maximilian Bockhorn · 14 shared papers, 2011–2018 · strength 0.63
  3. Jakob Robert Izbicki · 14 shared papers, 2011–2021 · strength 0.63
  4. Alexander Ioannis Damanakis · 3 shared papers, 2018–2020 · strength 0.42
  5. Christiane J. Bruns · 3 shared papers, 2018–2020 · strength 0.42
  6. Udo Schumacher · 5 shared papers, 2013–2021 · strength 0.32
  7. Raghu Kalluri · 2 shared papers, 2017–2026 · strength 0.30
  8. Kathleen M. McAndrews · 1 shared paper, 2026 · strength 0.24
  9. Paul A. Spezza · 1 shared paper, 2026 · strength 0.24
  10. Christoph Kahlert · 1 shared paper, 2026 · strength 0.24
  11. Daniel Wicklein · 4 shared papers, 2013–2021 · strength 0.23
  12. Marius Kemper · 2 shared papers, 2017–2021 · strength 0.20
  13. Yogesh Kumar Vashist · 5 shared papers, 2011–2015 · strength 0.18
  14. Emre F. Yekebas · 4 shared papers, 2011–2015 · strength 0.15
  15. Christine E. Engeland · 1 shared paper, 2024 · strength 0.15
  16. Rob C. Hoeben · 1 shared paper, 2024 · strength 0.15
  17. Claudia R. Ball · 1 shared paper, 2024 · strength 0.15
  18. Lukas J.A.C. Hawinkels · 1 shared paper, 2024 · strength 0.15
  19. Guy Ungerechts · 1 shared paper, 2024 · strength 0.15
  20. Selas T. F. Bots · 1 shared paper, 2024 · strength 0.15
  21. Theresa E. Schäfer · 1 shared paper, 2024 · strength 0.15
  22. Vera Kemp · 1 shared paper, 2024 · strength 0.15
  23. Achim Michael Aigner · 1 shared paper, 2021 · strength 0.11
  24. Katharina E. Effenberger · 2 shared papers, 2011–2018 · strength 0.10
  25. Felix Popp · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.